终末期肝病模型（MELD）评分在终末期肝病中的应用

希古日干; 苏雅; 佟静; 王炳元

doi:10.12449/JCH250325

终末期肝病模型（MELD）评分在终末期肝病中的应用

DOI: 10.12449/JCH250325

希古日干¹,
苏雅^1, , ,,
佟静²,
王炳元²

1.
内蒙古民族大学附属医院消化内科，内蒙古通辽 028000
2.
中国医科大学附属第一医院消化内科，沈阳 110001

基金项目:

国家自然科学基金青年项目 (8170030364)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：希古日干负责选题，总结文献，撰写文章；苏雅、佟静负责校对文献，修改论文；苏雅、王炳元负责校正论文写作思路并最后定稿。

详细信息

通信作者:
苏雅， suyajiayou2020@126.com （ORCID： 0009-0002-9193-3254）

计量
- 文章访问数: 1324
- HTML全文浏览量: 77
- PDF下载量: 36
- 被引次数: 0
出版历程
- 收稿日期: 2024-07-02
- 录用日期: 2024-08-15
- 出版日期: 2025-03-25

Application of Model for End-Stage Liver Disease score in end-stage liver disease

Rigan XIGU¹,
Ya SU^{1
, ,
,},
Jing TONG²,
Bingyuan WANG²

1.
Department of Gastroenterology，Affiliated Hospital of Inner Mongolia University for The Nationalities，Tongliao，Inner Mongolia 028000，China
2.
Department of Gastroenterology，The First Affiliated Hospital of China Medical University，Shenyang 110001，China

Research funding:

National Natural Science Foundation of China Young Scientist Fund (8170030364)

More Information

Corresponding author: SU Ya， suyajiayou2020@126.com （ORCID： 0009-0002-9193-3254）

摘要

摘要: 在全球范围内，终末期肝病模型（MELD）评分用来确定肝移植器官分配优先顺序。随着MELD评分的运作环境重点朝着病情较重的患者进行移植的方向发展，已经提出了几种模型来改进和提高MELD评分。MELD评分还用于非移植慢性肝病患者的管理。本文简要回顾了这些不同模型产生的背景，认为MELD产生的初衷是用于肝移植器官分配的优先顺序，肝移植评估之外的扩大应用应结合临床实际，个体化合理选择不同的MELD，以期患者得到最佳的预后评估、最佳的干预措施和最大的获益。
- 肝硬化 /
- 终末期肝病模型 /
- 疾病严重程度指数
Abstract: The Model for End-Stage Liver Disease （MELD） score is currently used to prioritize liver allocation for cirrhotic patients awaiting liver transplantation in the world. With the application of MELD score in transplantation for patients with severe conditions， several models have been proposed to refine and improve MELD score. MELD score has also been used for the management of non-transplantation patients with chronic liver disease. This article briefly reviews the background of these models and believes that the original intention of MELD is to determine the priority of organ allocation for liver transplantation. The expanded application of MELD score beyond liver transplantation assessment should be performed with reference to clinical practice， and different MELD models should be selected rationally based on individual conditions， in order to help patients achieve optimal prognosis assessment， intervention measures， and benefits.
- Liver Cirrhosis /
- Model for End-stage Liver Disease /
- Severity of Illness Index

HTML全文

参考文献(43)

[1]	SHARMA P, SCHAUBEL DE, SIMA CS, et al. Re-weighting the model for end-stage liver disease score components[J]. Gastroenterology, 2008, 135( 5): 1575- 1581. DOI: 10.1053/j.gastro.2008.08.004.
[2]	LEISE MD, KIM W RAY, KREMERS WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation[J]. Gastroenterology, 2011, 140( 7): 1952- 1960. DOI: 10.1053/j.gastro.2011.02.017.
[3]	BIGGINS SW, RODRIGUEZ HJ, BACCHETTI P, et al. Serum sodium predicts mortality in patients listed for liver transplantation[J]. Hepatology, 2005, 41( 1): 32- 39. DOI: 10.1002/hep.20517.
[4]	KIM W RAY, MANNALITHARA A, HEIMBACH JK, et al. MELD 3.0: The model for end-stage liver disease updated for the modern era[J]. Gastroenterology, 2021, 161( 6): 1887- 1895. e 4. DOI: 10.1053/j.gastro.2021.08.050.
[5]	STARLINGER P, AHN JC, MULLAN A, et al. The addition of C-reactive protein and von willebrand factor to model for end-stage liver disease-sodium improves prediction of waitlist mortality[J]. Hepatology, 2021, 74( 3): 1533- 1545. DOI: 10.1002/hep.31838.
[6]	ASRANI SK, JENNINGS LW, KIM WR, et al. MELD-GRAIL-Na: Glomerular filtration rate and mortality on liver-transplant waiting list[J]. Hepatology, 2020, 71( 5): 1766- 1774. DOI: 10.1002/hep.30932.
[7]	GARBER K. Controversial allocation rules for liver transplants[J]. Nat Med, 2002, 8( 2): 97. DOI: 10.1038/nm0202-97a.
[8]	MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31( 4): 864- 871. DOI: 10.1053/he.2000.5852.
[9]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33( 2): 464- 470. DOI: 10.1053/jhep.2001.22172.
[10]	WIESNER R, EDWARDS E, FREEMAN R, et al. Model for end-stage liver disease(MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124( 1): 91- 96. DOI: 10.1053/gast.2003.50016.
[11]	OLTHOFF KM, BROWN RS Jr, DELMONICO FL, et al. Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA[J]. Liver Transpl, 2004, 10(10 Suppl 2): A6- 22. DOI: 10.1002/lt.20247.
[12]	WIESNER R, LAKE JR, FREEMAN RB, et al. Model for end-stage liver disease(MELD) exception guidelines[J]. Liver Transpl, 2006, 12(12 Suppl 3): S85- S87. DOI: 10.1002/lt.20961.
[13]	LIM YS, LARSON TS, BENSON JT, et al. Serum sodium, renal function, and survival of patients with end-stage liver disease[J]. J Hepatol, 2010, 52( 4): 523- 528. DOI: 10.1016/j.jhep.2010.01.009.
[14]	ASRANI SK, KAMATH PS. Model for end-stage liver disease score and MELD exceptions: 15 years later[J]. Hepatol Int, 2015, 9( 3): 346- 354. DOI: 10.1007/s12072-015-9631-3.
[15]	QUANTE M, BENCKERT C, THELEN A, et al. Experience since MELD implementation: How does the new system deliver?[J]. Int J Hepatol, 2012, 2012: 264015. DOI: 10.1155/2012/264015.
[16]	D’AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44( 1): 217- 231. DOI: 10.1016/j.jhep.2005.10.013.
[17]	TEH SH, NAGORNEY DM, STEVENS SR, et al. Risk factors for mortality after surgery in patients with cirrhosis[J]. Gastroenterology, 2007, 132( 4): 1261- 1269. DOI: 10.1053/j.gastro.2007.01.040.
[18]	KAMATH PS, KIM W RAY, GROUP ALDS. The model for end-stage liver disease(MELD)[J]. Hepatology, 2007, 45( 3): 797- 805. DOI: 10.1002/hep.21563.
[19]	KREMERS WK, VAN IJPEREN M, KIM WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients[J]. Hepatology, 2004, 39( 3): 764- 769. DOI: 10.1002/hep.20083.
[20]	KIM MS, KATO TS, FARR M, et al. Hepatic dysfunction in ambulatory patients with heart failure: Application of the MELD scoring system for outcome prediction[J]. J Am Coll Cardiol, 2013, 61( 22): 2253- 2261. DOI: 10.1016/j.jacc.2012.12.056.
[21]	MITRA A, MYERS L, AHN J. Assessing the severity and prognosis of alcoholic hepatitis[J]. Clin Liver Dis, 2021, 25( 3): 585- 593. DOI: 10.1016/j.cld.2021.03.004.
[22]	JOPHLIN LL, SINGAL AK, BATALLER R, et al. ACG clinical guideline: Alcohol-associated liver disease[J]. Am J Gastroenterol, 2024, 119( 1): 30- 54. DOI: 10.14309/ajg.0000000000002572.
[23]	FORREST EH, ATKINSON SR, RICHARDSON P, et al. Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis[J]. J Hepatol, 2018, 68( 3): 511- 518. DOI: 10.1016/j.jhep.2017.11.017.
[24]	MORALES-ARRÁEZ D, VENTURA-COTS M, ALTAMIRANO J, et al. The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: A global study[J]. Am J Gastroenterol, 2022, 117( 2): 301- 310. DOI: 10.14309/ajg.0000000000001596.
[25]	FINK MA, ANGUS PW, GOW PJ, et al. Liver transplant recipient selection: MELD vs. clinical judgment[J]. Liver Transpl, 2005, 11( 6): 621- 626. DOI: 10.1002/lt.20428.
[26]	HEUMAN DM, ABOU-ASSI SG, HABIB A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death[J]. Hepatology, 2004, 40( 4): 802- 810. DOI: 10.1002/hep.20405.
[27]	BIGGINS SW, KIM W RAY, TERRAULT NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130( 6): 1652- 1660. DOI: 10.1053/j.gastro.2006.02.010.
[28]	KALRA A, WEDD JP, BIGGINS SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more[J]. Curr Opin Organ Transplant, 2016, 21( 2): 120- 126. DOI: 10.1097/MOT.0000000000000281.
[29]	SHARMA P, SCHAUBEL DE, GOODRICH NP, et al. Serum sodium and survival benefit of liver transplantation[J]. Liver Transpl, 2015, 21( 3): 308- 313. DOI: 10.1002/lt.24063.
[30]	KIM JJ, KIM JH, KOO JK, et al. The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites[J]. Clin Mol Hepatol, 2014, 20( 1): 47- 55. DOI: 10.3350/cmh.2014.20.1.47.
[31]	CHETWOOD JD, WELLS MG, TSOUTSMAN T, et al. MELD-GRAIL and MELD-GRAIL-Na are not superior to MELD or MELD-Na in predicting liver transplant waiting list mortality at a single-center level[J]. Transplant Direct, 2022, 8( 7): e1346. DOI: 10.1097/TXD.0000000000001346.
[32]	THABUT D, MASSARD J, GANGLOFF A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J]. Hepatology, 2007, 46( 6): 1872- 1882. DOI: 10.1002/hep.21920.
[33]	CAZZANIGA M, DIONIGI E, GOBBO G, et al. The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome[J]. J Hepatol, 2009, 51( 3): 475- 482. DOI: 10.1016/j.jhep.2009.04.017.
[34]	BLAYA D, RUBIO-TOMÁS T, RODRIGO-TORRES D, et al. Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis[J]. Hepatol Int, 2021, 15( 4): 1006- 1017. DOI: 10.1007/s12072-021-10165-y.
[35]	WOOD NL, VANDERWERKEN D, SEGEV DL, et al. Correcting the sex disparity in MELD-Na[J]. Am J Transplant, 2021, 21( 10): 3296- 3304. DOI: 10.1111/ajt.16731.
[36]	LOCKE JE, SHELTON BA, OLTHOFF KM, et al. Quantifying sex-based disparities in liver allocation[J]. JAMA Surg, 2020, 155( 7): e201129. DOI: 10.1001/jamasurg.2020.1129.
[37]	European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
[38]	KIM W RAY, MANNALITHARA A, KWO PY, et al. Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40[J]. Hepatology, 2023, 77( 3): 851- 861. DOI: 10.1002/hep.32770.
[39]	SINGEAP AM, MINEA H, PETREA O, et al. Real-world utilization of corticosteroids in severe alcoholic hepatitis: Eligibility, response, and outcomes[J]. Medicina(Kaunas), 2024, 60( 2): 311. DOI: 10.3390/medicina60020311.
[40]	KWONG AJ, EBEL NH, KIM WR, et al. OPTN/SRTR 2020 annual data report: Liver[J]. Am J Transplant, 2022, 22( Suppl 2): 204- 309. DOI: 10.1111/ajt.16978.
[41]	MAZUMDER NR, FONTANA RJ. MELD 3.0 in advanced chronic liver disease[J]. Annu Rev Med, 2024, 75: 233- 245. DOI: 10.1146/annurev-med-051322-122539.
[42]	PAPASTERGIOU V, TSOCHATZIS EA, PIERI G, et al. Nine scoring models for short-term mortality in alcoholic hepatitis: Cross-validation in a biopsy-proven cohort[J]. Aliment Pharmacol Ther, 2014, 39( 7): 721- 732. DOI: 10.1111/apt.12654.
[43]	LA DÍAZ, FUENTES-LÓPEZ E, AYARES G, et al. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis[J]. JHEP Rep, 2023, 5( 8): 100727. DOI: 10.1016/j.jhepr.2023.100727.